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Abstract
The effects of both the amount and quality of dietary fat have been studied intensively during the past
decades. Previously, low-fat diets were recommended without much attention to the quality of fat, whereas
there is general emphasis on the quality of fat in current guidelines. The objective of this systematic review
(SR) was to assess the evidence of an effect of the amount and type of dietary fat on body weight
(BW), risk factors, and risk of non-communicable diseases, that is, type 2 diabetes (T2DM), cardiovascular
diseases (CVD), and cancer in healthy subjects or subjects at risk for these diseases. This work was performed
in the process of updating the fourth edition of the Nordic Nutrition Recommendations from 2004.
The literature search was performed in October 2010 covering articles published since January 2000.
A complementary search was done in February 2012 covering literature until December 2011. Two authors
independently selected articles for inclusion from a total of about 16,000 abstracts according to predefined
criteria. Randomized controlled trials (RCT) and prospective cohort studies (PCS) were included as well as
nested casecontrol studies. A few retrospective casecontrol studies were also included when limited or no
data were available from other study types. Altogether 607 articles were quality graded and the observed
effects in these papers were summarized. Convincing evidence was found that partial replacement of saturated
fat (SFA) with polyunsaturated fat (PUFA) or monounsaturated fat (MUFA) lowers fasting serum/plasma
total and LDL cholesterol concentrations. The evidence was probable for a decreasing effect of fish oil on
concentration of serum/plasma total triglycerides as compared with MUFA. Beneficial effect of MUFA
both on insulin sensitivity and fasting plasma/serum insulin concentration was considered as probable in
comparisons of MUFA and carbohydrates versus SFA, whereas no effect was found on fasting glucose
concentration in these comparisons. There was probable evidence for a moderate direct association between
total fat intake and BW. Furthermore, there was convincing evidence that partial replacement of SFA with
PUFA decreases the risk of CVD, especially in men. This finding was supported by an association with
biomarkers of PUFA intake; the evidence of a beneficial effect of dietary total PUFA, n-6 PUFA, and
linoleic acid (LA) on CVD mortality was limited suggestive. Evidence for a direct association between total
fat intake and risk of T2DM was inconclusive, whereas there was limited-suggestive evidence from bio-
marker studies that LA is inversely associated with the risk of T2DM. However, there was limited-suggestive
evidence in biomarker studies that odd-chain SFA found in milk fat and fish may be inversely related to
T2DM, but these associations have not been supported by controlled studies. The evidence for an association
between dietary n-3 PUFA and T2DM was inconclusive. Evidence for effects of fat on major types of cancer
was inconclusive regarding both the amount and quality of dietary fat, except for prostate cancer where there
was limited-suggestive evidence for an inverse association with intake of ALA and for ovarian cancer for
which there was limited-suggestive evidence for a positive association with intake of SFA. This SR reviewed
a large number of studies focusing on several different health outcomes. The time period covered by the
search may not have allowed obtaining the full picture of the evidence in all areas covered by this SR.
However, several SRs and meta-analyses that covered studies published before year 2000 were evaluated,
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(page number not for citation purpose)which adds confidence to the results. Many of the investigated questions remain unresolved, mainly because
of few studies on certain outcomes, conflicting results from studies, and lack of high qualitycontrolled
studies. There is thus an evident need of highly controlled RCT and PCS with sufficient number of subjects
and long enough duration, specifically regarding the effects of the amount and quality of dietary fat on
insulin sensitivity, T2DM, low-grade inflammation, and blood pressure. New metabolic and other potential
risk markers and utilization of new methodology in the area of lipid metabolism may provide new insight.
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T
he role of dietary fat in health has been under inten-
sive research and debate during the past decades.
In some countries, for example, in Finland, there
has been a dramatic decline in coronary heart disease
(CHD) mortality along with decreased intake of fat,
in particular saturated fat (SFA) (1). Low-fat diets have
previously been recommended by some official bodies
without much attention to the quality of fat, whereas
current guidelines generally put more emphasis on the
quality of fat (24). The quality of fat is generally spe-
cified by the relative content of SFA, monounsaturated
(MUFA), and polyunsaturated fatty acids (PUFA) in-
cluding the proportion or amount of essential fatty acids,
that is, linoleic acid (LA) and a-linolenic acid (ALA),
as well as the proportion or amount of long-chain n-3
fatty acids (n-3 LCPUFA), that is, eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA).
In many observational studies, the total amount of
dietary fat has been shown to have only a minor, and
in most studies even no effect on the risk of lifestyle
diseases, for example, cardiovascular diseases (CVD),
type 2 diabetes mellitus (T2DM), and cancer or the level
of the risk factors of these diseases, or markers of the
cardiometabolic syndrome, including abdominal adipos-
ity, blood pressure (BP), serum lipid profile, and mea-
sures of insulin sensitivity (2). On the contrary, the
quality of fat has been shown to have a significant effect
on serum lipid profile and BP as well as endothelial
function and low-grade inflammation and has further-
more, been shown to affect the riskof CVD either in itself
or as an important component of a health promoting diet
(2, 59).
The objective of this systematic review (SR) was to
assess the effect and grade of the evidence of the amount
and type of dietary fat as well as biomarkers of the
quality of dietary fat on risk factors, body weight (BW),
and risk of non-communicable diseases, that is, T2DM,
CVD (including CHD and stroke), and cancer. This work
was performed in the process of updating the fourth
edition of the Nordic Nutrition Recommendations
(NNR) from 2004 (10).
Methods
Research questions
The research questions were:
1. What are the effects of intake of total fat and
various combinations and proportions of fatty
acid classes in the diet, considering intake of other
energy-giving nutrients, on
a. well-established indicators of clinical outcomes
such as plasma or serum total lipids and lipo-
protein concentrations, plasma or serum glucose
and insulin concentrations, BP, and markers
of low-grade inflammation?
b. clinical outcomes including BW, T2DM, CVD,
cancer, and all-cause mortality?
2. What is the association between the biomarkers of
the quality of dietary fat and the above-mentioned
outcomes (namely a and b).
Birth outcomes, growth and development, and mainte-
nance of body functions were included in the systematic
literature search as well, but these topics were transferred
to the expert groups of pregnancy and lactation, and
children and the elderly and are not included in this
review. Studies assessing the effect of minor dietary fat
components such as trans-fatty acids (TFA), conjugated
linoleic acid (CLA), or dietary cholesterol were not in-
cluded in this SR and neither were studies assessing the
effect of dietary fat intake on postprandial lipemia.
Inclusion criteria
The a priori defined inclusion criteria were as follows:
1. Publication year: January 2000October 2010 (first
search), until February 2012 in the complementary
search. A few papers were identified through re-
ference lists. Relevant SRs published after searches
were also evaluated.
2. Publication type: Only original articles, for re-
search questions 1b and 2b also SRs.
To access the supplementary material to this article please see Supplementary files under Article Tools online
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prospective cohort studies (PCS), and nested case
control studies (NCC). Retrospective casecontrol
studies (RCC) were included only if data were not
available from other study types or there were only
very few studies available. Cross-sectional studies
and animal studies were excluded.
4. Subjects: Aged 1870. Healthy, that is, disease-free
subjects at baseline, but subjects with dyslipidemia,
glucose intolerance, or overweight (mean body
mass index (BMI) of the study population not
exceeding 30 kg/m
2) were included. Studies with-
out Caucasians or Caucasians as clear minority
were excluded.
5. Number of participants for RCTs: ]10 in cross-
over studies, and per group in studies with parallel
design.
6. Intervention/exposure: The amount and/or quality
of dietary fat.
7. Dietary assessment methods: food record, food
frequency questionnaire (FFQ), dietary recall, or
valid biomarkers.
8. Nutrient database used: Updated and relevant to
the country where the study was performed.
9. Length of the study: Minimum of 4 weeks in RCTs
except in studies on BW and body composition
where a minimum of 6 months was required. PCS
h a dt oh a v eaf o l l o w - u po f 4 years whereas studies
on cancer had to have a follow-up of  5 years in.
10. Dropout rate in RCTs: B30% in 6 months, B40%
in 12 months, B50% in 24 months.
Search methods and terms
The search strategy is presented in Appendix 1. The
literature search was performed by an independent
librarian. The first search was run in October 2010 by
the PubMed platform supplied by the United States
National Library of Medicine (http://www.ncbi.nlm.nih.
gov/pubmed). An additional search for papers on in-
flammatory markers as well as papers of relevance for
research questions 1a and 1b was committed in January
February 2012. Finally, a complementary search was
performed in order to include the most recent articles
(published before December 31, 2012) to see whether
there is a need to reformulate the conclusions made based
on the first search and the additional search. SweMed/
SweMed databases, supplied by the Karolinska Insti-
tute in Sweden (http://micr.kib.ki.se/), were also included
in the complementary search. Few additional papers
found in the complementary search were included in
the quality grading because a small number of studies on
the specific issue.
Selection of articles
The list of abstracts for each research question was
evaluated independently by two experts. In case at least
one of the experts found the abstract eligible, the article
was ordered in full text. If additional potential relevant
papers were identified after going through the literature
lists, abstracts, and full-text papers, these were ordered in
full text and reviewed by two independent experts. The
experts jointly decided which articles to include. Only the
papers, which both experts found ineligible after the full-
text review, were excluded before the quality assessment,
and all these are listed in Appendix 2 with reasons for
exclusion.
Quality assessment and grading of evidence
The included full-text papers were quality assessed inde-
pendently by two experts using individual quality assess-
ment tools (QAT) for RCT, PCS, or RCC (see SLR
Guidelines on the homepage of the fifth Nordic Nutrition
Recommendation (NNR5, www.nnr5.org). SRs were in-
cluded in the research questions 2a and 2b and they were
quality assessed by a specific QAT. The QATs included
a number of questions regarding several aspects of the
study including study design, population characteristics,
exposure measure, and outcome measures (NNR5 SLR
Guide, www.nnr5.org).
The quality was assessed for all included studies in
categories from A to C: A (a high-quality study with very
low risk of bias), B (good-quality study, some bias, but
not enough to invalidate the results), and C (low-quality
study, significant bias and weaknesses which may invali-
date the results). The quality assessment was cross-checked
with the two assessors and potential disagreement was
discussed within the group. Papers graded as A or B
were included in the evidence tables (Appendices 36),
where the results were arranged according to the inter-
vention/exposure and the outcome. The results of the
quality assessment of the individual studies were sum-
marized to evaluate the quality and strength of the overall
evidence in relation to the posed research questions
(Tables 14). The evidence for each exposureoutcome
association was categorized according to the directions
given by the NNR5 committee guidelines into four cate-
gories: convincing (high), probable (moderate), limited-
suggestive (low), and limited-no conclusion (insufficient).
Results
In total, 8,398 abstracts from the first search, 6,111 from
the additional search, and 1,409 from the complementary
search were screened for eligibility (Fig. 1), of which
733 were on birth outcomes, growth and development,
and maintenance of body functions. Full-text papers of
potential relevance for the research questions in this
review were ordered for 704 of the abstracts. In addition,
89 papers from other sources were included. Altogether
151 papers were found ineligible after thorough examina-
tion, and 35 were for birth outcomes, growth, devel-
opment and maintenance of body functions, and not
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in the quality grading.
The reasons for exclusion of papers before the quality
assessment were: 1) the aim of the study was out
of the scope of the research questions; 2) the studied
exposure was a food pattern or a whole food, e.g. almods
or fish. 3) the study design was not in accordance with
the inclusion criteria, for example, uncontrolled inter-
vention or non-randomized study; 4) there were too few
subjects or the subjects were non-healthy or obese or
only from a non-Caucasian population; 5) the duration
of the study was too short; or 6) there were no data on
nutrient composition.
The results of all 607 quality-assessed studies are pre-
sented in evidence tables in Appendices 36. The com-
bined results, that is, a summary of the graded evidence
are presented in Appendices 710. In general, there were
very few studies which were quality graded as A and the
most of the papers were graded as B or C (Fig. 1). The
most frequent reasons for not meeting grade A were lack
of valid biomarkers for measuring compliance to the
dietary exposure, for example, fatty acid composition of
serum/plasma lipids, lackof power calculations, problems
in the quality of randomization and blinding, lack of a
clear compliance reporting, and lack of reporting of the
food composition database. A limiting factor for many
of the PCS was that only one baseline dietary assess-
ment was available and that the response rate was low
or not stated. Multiple testing was also quite common in
the PCS.
Almost all of the included studies for research question
1a were RCTs  only one was a PCS. Studies graded as C
were not tabulated because of abundance in B-graded
studies. Most studies in research question 1b were PCS
(except for the studies on BW which were mainly RCT).
In addition to studies graded as A or B, studies graded
as C were tabulated for certain of the outcomes in re-
search question 1b because of the low number of studies
(e.g. certain types of cancer). For research questions 2a
and 2b, only PCS were included, including NCC and
other prospective case-cohort studies, but RCC studies
were not included. All of the studies included for research
question 2a and 2b were graded as B.
Plasma or serum lipid profile
This SR includes altogether 45 studies on the intake of
dietary fat  both total amount and quality  and serum
or plasma lipid profile (Appendix 3, Table 1a), and the
overall evidence from these studies is summarized in
Appendix 7, Table 1a. The specific evidence regarding
effects of amounts and types of fat on apolipoprotein
concentrations, apoB and apoA-I, are not given in detail
because these data in general follow the data of LDL and
HDL cholesterol concentrations (LDL-C and HDL-C),
respectively. Furthermore, these variables are not gener-
ally used in clinical work to assess the risk of CVD.
MUFA and/or PUFA versus SFA. There were nine
studies with randomized comparisons of unsaturated fat
(MUFA and/or PUFA) versus SFA (1119). One of these
studies was a comparison of margarine versus butter (12),
the others were comparisons between fatty acid classes.
The proportion of SFA in these studies was roughly 13
19% of energy (E%) in the SFA diet and MUFA 1421
E% in the unsaturated fatenriched diet. There were two
studies in which SFA and PUFA were compared. The
proportion of SFA was about 20 E% or 52% of the total
fat in the SFA diet and the proportion of PFA was about
9 E% or 41% of total fat in the PUFA diet (14, 17). All
of these nine studies found that fasting plasma/serum
cholesterol concentration was lower after a diet rich in
MUFA and/or PUFA compared with a diet rich in SFA.
The evidence was, therefore, considered as convincing.
The evidence was also considered as convincing regarding
the effect of MUFA and/or PUFAversus SFA on plasma/
serum LDL-C concentration, because eight out of nine
studies found that diets rich in unsaturated fatty acids
resulted in lower concentrations as compared with diets
Fig. 1. Flow chart.
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periods was not significant (15). The overall evidence for
the effect of MUFA and/or PUFAversus SFA on HDL-C
was categorized as limited-no conclusion, as diets rich in
MUFA and/or PUFA as compared with a diet rich in
SFA were found to result in lower plasma/serum HDL-C
concentration in three studies, higher concentration in
one study, and no difference between the diets in five
studies. Fasting plasma/serum triglyceride (TAG) con-
centration was examined in eight of the nine studies. A
diet rich in MUFA and/or PUFA was found to result in
lower concentration in two studies, whereas six studies
showed no difference between the diets  thus association
is unlikely.
MUFA and/or PUFA versus CHO. Seven of the in-
cluded studies compared diets enriched in MUFA (five
studies) or both MUFA and PUFA (two studies) with
diets rich in carbohydrates (CHO) with respect to effects
on concentrations of plasma/serum total cholesterol,
LDL-C and HDL-C, and total TAG (MUFA: (2024);
both MUFA and PUFA: (25, 26)) and one study that
only assessed the effect of MUFA on TAG concentra-
tions (27). The mean proportion of dietary CHO in these
studies ranged from 50 to 58 E% and that of MUFA from
20 to 25 E%. One of the studies used an overall energy-
restricted diet (6,000 kJ), which supplied with 35 or
12 E% of fat of which 20 versus 4 E% was provided by
MUFA (21). In five of the studies, plasma/serum total
cholesterol concentration did not differ between the diets,
whereas in one study it was found to be lower in a diet
rich in unsaturated fat (25) and in one study in a diet rich
in CHO (21). The concentration of plasma/serum LDL-
C did not differ between the diets in any of the seven
studies, whereas HDL-C was lower in a CHO diet in
three studies (21, 23, 25). The four other studies showed
no difference between the diets. Plasma/serum total TAG
concentration was lower in a diet rich in MUFA and/or
PUFA in three studies (20, 23, 25), whereas no difference
between the diets was observed in the other five studies.
The evidence was considered as unlikely regarding LDL-
C concentration and limited-no conclusion for concen-
trations of serum/plasma total cholesterol, HDL-C and
TAG.
Fish oil/n-3 LCPUFA versus MUFA. The effect of fish
oil supplementation, that is, n-3 LCPUFA, on serum lipid
profile was compared with MUFA (olive oil) in seven
studies (2834). One of these studies (28) did not report
effects on plasma/serum total cholesterol concentration.
Three of these studies specifically compared the effect
of DHA with MUFA (29, 30, 34). The amount of n-3
LCPUFA given in the studies ranged from 0.7 to 6 g/day.
In the KANWU study (31), diets enriched either in SFA
or MUFA were supplemented with fish oil 3.6 g/day or
placebo (olive oil).
Intake of n-3 LCPUFA was found to result in higher
plasma/serum total cholesterol concentration in two stu-
dies with 2.1 g/day DHADPA (32) or 0.7 g/day DHA
(34). No difference was observed in four studies; two
studies with 3 or 4 g/day of both EPA or DHA (29, 30),
one with 3.6 g/day fish oil (31), and one with a dose
response of EPADHA from 0.45 to 1.8 g/day (33).
The effect of n-3 LCPUFA on plasma/serum LDL-C
concentration was reported in seven studies. In two
studies it was found to be higher after the intake of fish
oil of 3.6 g/day or 6 g/day (28, 31). Three studies ex-
amined the effect of DHAversus MUFA (29, 32, 34) and
found higher LDL-C concentration after DHA; in two
studies with an intake of DHA of either 4 or 0.7 g/day,
respectively (29, 34), and one study with an intake of
1.5 g/day DHA0.6 g/day of DPA (32). In the study
with either 3 g/day of EPA or DHA there was no dif-
ference between the groups  neither between the n-3
LCPUFA nor as compared with MUFA (30). In a study
by Sanders et al. (33), combined doses of 0.45 g, 0.9 g, or
1.8 g per day of EPA and DHA with an EPA-to-DHA
ratio of 1.51 did not find any difference compared with
MUFA.
In five studies, fish oil resulted in lower TAG concen-
tration than MUFA (2831, 33), whereas no differences
were seen in two studies that compared either DHA and
DPA (32) or DHA (34) with MUFA. DHA resulted in a
higher HDL-C concentration in one study (32), whereas
two studies that compared DHA, EPA, and olive oil
found no difference (29, 30). In the study by Theobald
et al. (34), HDL-C concentration increased in subjects
who received DHA during the first period of the study.
In one study, fish oil resulted in higher plasma HDL-C
concentration compared with MUFA (olive oil) (28),
whereas no difference was found in two other studies
(31, 33).
The evidence was considered as limited-suggestive re-
garding the effect of DHAversus MUFA on LDL-C con-
centration and limited-no conclusion for the effect of
DHA on concentrations of TAG. The evidence regarding
fish oil versus MUFA was considered as limited-no con-
clusion for the effect on concentrations of plasma/serum
total cholesterol, LDL-C, and HDL-C, and as probable
for the effect on plasma/serum TAG.
Fish oil/n-3 LCPUFAversus other PUFA. No difference
on plasma/serum total cholesterol concentration was found
in any of the seven studies that compared fish oil with
different types of other PUFA, that is, EPA and DHA
with gamma-linolenic acid (an n-6 PUFA) (35), EPA or
DHA with ALA (36), fish oil with ALA (37), or PUFA
rich vegetable oils (corn, soybean, evening primrose, or
black currant seed oils) (3841). LDL-C concentration
was higher after a fish oil period in three studies (37, 39,
41), whereas no difference was observed in four studies
(35, 36, 38, 40). In one study, fish oil of 4 g/day was found
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the other six studies no effect on HDL-C concentration
was found (3538, 40, 41). Plasma TAG concentration
was found to be lower in four studies (3740), but not in
the studies of Egert et al. (36), Laidlaw and Holub (35),
and Tahvonen et al. (41). The effect of fish oil relative
to other source of PUFA on concentrations of TAG,
LDL-C, and HDL-C was considered as limited-no con-
clusion. The evidence for an effect on plasma/serum total
cholesterol concentration was considered as unlikely.
Diet studies. When a diet according to nutrition recom-
mendations was compared with a control diet (42, 43), a
recommended diet resulted in lower plasma/serum LDL-
C concentration. Total cholesterol concentration was
lower in the study by Brekke et al. (42) at 2 years. There
was no difference in HDL-C concentration. In a study
including physical activity (43), TAG concentration was
lower on a recommended diet (25 E% fat, 7 E% SFA),
whereas in the study by Brekke et al. (42), no difference in
TAG concentration was found between the groups.
LDL and VLDL particle size
There were seven studies in which the effect of the amount
or quality of fat on LDL and VLDL particle size was
studied (Appendix 3, Table 1b). The total intake offat was
not found to have an effect on LDL particle size (44).
When comparing the effect of the intakes of SFA and
MUFA, one study showed a favorable, that is, increased,
effect of MUFA on LDL particle size (16), whereas no
difference was found in one study (31). Intake of n-3
LCPUFA was also found to increase LDL particle size.
This was shown in a study which compared n-3 LCPUFA
from fish oil (1.6 E% n-3 PUFA) with ALA (1.2 E% n-3
PUFA) (37) or when fish oil (3 g/day) together with LA
was compared with ALA or LA, of which LA was used
as a control (45). ALA (1.1 E%) was found to have a
favorable, that is, decreasing effect on VLDL particle size
when comparedwith LA, that is, a low-ALA diet (0.4 E%)
(46). DHAwas found to result in the largest LDL particle
size as comparedwith EPA and MUFA (olive oil) (4 g/day
each) (29). The effect of LA, ALA, and n-3 LCPUFA on
LDL particle size was considered as limited-no conclusion.
The effect of the amount of fat and the effect of MUFA as
compared either with SFA or EPA/DHA was considered
as limited-no conclusion (Appendix 7, Table 1b).
Summary. There is convincing evidence that partial
replacement of SFAwith PUFA or MUFA lowers fasting
total and LDL-C concentrations, and data suggest that
there is no effect on TAG concentration. The evidence
for HDL-C was found to be limited-no conclusion. The
evidence of an effect of the replacement of CHO with
PUFA or MUFA on plasma/serum concentrations of
total cholesterol, TAG, and HDL-C was found to be
limited-no conclusion, whereas an effect of replacing CHO
with PUFA or MUFA on LDL-C concentration was
considered unlikely. The evidence for the different effect
of DHA than MUFA on LDL-C concentration was con-
sidered as limited-suggestive whereas the effect on con-
centrations of TAG was considered as limited-no conclusion.
On the contrary, the evidence regarding fish oil/n-3
LCPUFA versus MUFA was considered as probable for
the effect on plasma/serum TAG concentration. An effect
of fish oil/n-3 LCPUFA versus MUFA on plasma/serum
total cholesterol concentrations was judged as limited-no
conclusion.
Insulin sensitivity and plasma/serum insulin and glucose
concentrations
There are 11 studies included in this SR regarding the
amount and quality of dietary fat on insulin sensitivity
and 20 on fasting serum/plasma insulin concentrations
(Appendix 3).
Insulin sensitivity
The effect of MUFA versus SFA on insulin sensitivity
measured either by insulin sensitivity index SI or home-
ostasis model insulin resistance (HOMA-IR) was exam-
ined in four studies (11, 15, 18, 19) and the effect of
PUFA versus SFA in one study (17). Insulin sensitivity
was better on MUFA (MUFA 13 E% vs. 21 E%) in one
study (19) and on PUFA (about 8 vs. 22 E%) in one other
study (17). In three studies there was no difference.
When MUFA and CHO were compared with SFA
(24, 4749), MUFA resulted in better HOMA-IRor SI in
all studies, and in one study CHO also resulted in better
SI than SFA. The intake of MUFA in the MUFA diet
ranged from 20 to 24 E%, and the intake of SFA in the
SFA diet ranged from 15 to 23 E%. Because of small
number of subjects, altogether 229 in four studies, the
strength of evidence was graded as probable regarding the
effect of MUFA versus SFA in studies in which both
MUFA and CHO were compared with SFA.
When diets supplemented with fish oil or a plant
source of n-3 fatty acids (ALA) were compared, no dif-
ference in SI was found (37). When added either to the
diet high in MUFA or SFA, fish oil providing 2.1 g/day
EPA and 1.5 g/day DHA did not have an effect on SI,
first phase insulin secretion, disposition index or KG (50).
Plasma/serum insulin concentrations
Fasting plasma/serum insulin concentration was lower on
a MUFA-rich diet in two studies (47, 48), and on MUFA-
and CHO-rich diets in two studies (27, 49) as compared
with a SFA-rich diet. When an isocaloric replacement
of MUFA (11, 15, 19) or PUFA (17) was compared with
SFA, three studies showed no difference, whereas one
study showed a favorable effect for MUFA (19).
In studies comparing MUFA with CHO (21, 22, 24),
fish oil, with no fish oil, or ALA (37, 41, 50, 51), a
recommended diet with a generally consumed diet (42) or
a low-fat diet with a low-fat PUFA-enriched diet with or
Ursula Schwab et al.
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intervention periods was found. A low-fat diet (26 E%)
resulted in lower insulin concentration in one study after
both 1 and 5 years as compared with a general diet (53).
Avery low-fat diet (20 E%) did not differ from a generally
recommended diet (37 E%) in terms of fasting plasma/
serum insulin concentration (54).
In summary, in comparisons of MUFA versus CHO
versus SFA, the beneficial effect of MUFA both on in-
sulin sensitivity and fasting insulin concentration was con-
sidered as probable. In comparisons of MUFA or PUFA
versus SFA, the evidence was considered as limited-no
conclusion (Appendix 7).
Plasma/serum glucose concentration
There are 20 studies included in this SR on the amount
and quality of dietary fat on fasting serum/plasma glucose
concentrations (Appendix 3, Table 1c).
The effect of MUFA (14 to 21 E%) on fasting plasma/
serum glucose concentration was compared with SFA
(15 to 31 E%) in three studies (11, 15, 19) and with SFA
(15 to 23 E%) and CHO (57 to 58 E%) in four studies
with MUFA ranging from 20 to 22 E% (27, 4749). In
one study, PUFA was compared with SFA (17). When
unsaturated fat (MUFA or PUFA) was compared with
SFA, no difference was found in any of the four studies.
When CHO were included in the comparison, MUFA
resulted in better fasting glucose concentration in one
study (48), whereas in other three studies no difference
between the periods was found.
When MUFA was compared with CHO (21, 22, 24), a
MUFA-rich diet (23 E% MUFA, 40 E% CHO) resulted
in better fasting plasma/serum glucose concentration
than a diet with a higher CHO intake (52 E% CHO,
11 E% MUFA) in one study (22), whereas in two other
studies no difference was found. Of these studies, one was
conducted with a low calorie diet (6,000 kJ) (21). When
diets with added fish oil were compared with diets with
no fish oil or ALA or stearidonic acid, (C18:4 n-3) (37,
41, 50, 51) no difference in glucose concentration was
found in three studies, whereas in one study in healthy
young females a fish oil supplement of 2.8 g/day resulted
in lower glucose concentration compared with 3 g/day of
black currant seed oil, a source of stearidonic acid (41).
A recommended diet resulted in better glucose con-
centration in one study including also physical activity
(43), whereas in another study a recommended diet with-
out physical activity intervention no effect was found (42).
Neither was there any effect of a fat-reduced diet (30 E%)
or fat-reduced, PUFA-enriched diet with or without
energy restriction (52). A low-fat diet (26 E%) resulted
in better glucose concentration in one study after a 5-year
intervention, whereas no difference was seen after 1 year
as compared with a general diet (53). A very low-fat diet
(20 E%) did not differ from a generally recommended diet
(37 E%) in terms of glucose concentration (54).
In summary, an effect of replacement of SFA with
MUFA or PUFA on fasting plasma/serum glucose con-
centration was considered as unlikely. The evidence of
the effect of other type of modification of the quality
of fat or replacement of fat with CHO on fasting glu-
cose concentrations was considered limited-no conclusion
(Appendix 7, Table 1c).
Blood pressure
Altogether 14 RCTs were included in this SR regarding
the quality and amount of dietary fat on BP (Appendix 3,
Table 1d). Three RCTs compared the intake of MUFA
with SFA in a total of 647 subjects. One PCS with 28,100
subjects also included this comparison. A diet enriched
in MUFA (2021 E%) and reduced SFA resulted in
lower BP in two of the RCTs (55, 56). In the study by
Rasmussen et al. (56) in which ambulatory BP was mea-
sured, the response to a MUFA-enriched diet (21 E%) was
pronounced when the amount of total fat was B37 E%
compared with a total fat intake 37 E% or above. In the
RCT by Bos et al. (11) and in the PCS by Wang et al.
(57), the quality of dietary fat did not affect BP. When
unsaturated fat was compared with CHO, an unsaturated
fat enriched diet resulted in lower BP in one study (25),
whereas the other study showed no difference between
MUFA and CHO (21). A recommended diet including
also physical activity did not affect BP as compared with
an average diet (43), whereas a very low-fat diet (20 E%)
resulted in a lower BP than a generally recommended
diet (37 E%) (54). Overall, the evidence for an associa-
tion between total fat, proportions of SFA, MUFA or
total unsaturated fat and BP was limited-no conclusion
(Appendix 7, Table 1d).
The effect of fish oil supplements (2.14 g/day) on BP
has been examined in three RCT studies in comparison
with dietary sources of ALA and/or LA (38, 45, 58). Two
of the studies did not find any difference between the
diets, whereas one study found that a higher intake of
EPADHA (3.6 g/day) resulted in lower BP as com-
paredwith a lower intake of EPADHA (1.2 g/day), low
ALA (2.2 g/day), or high ALA (6.6 g/day) (58). Fish oil
12 g/day resulted in lower mean arterial BP than SFA in
an energy-restricted settings (59). Furthermore, no dif-
ference between the groups was found in the study by
Sanders et al. (32), which compared the intake of DHA
and DPA (1.50.6 g/day) with MUFA from olive oil.
The evidence for an effect of the quality or the amount
of dietary fat was considered as limited-no conclusion
(Appendix 7, Table 1d).
Coagulation factors, platelet aggregation, inflammatory
markers, endothelial function, and intima media thickness
In five studies the effect of the quality of dietary fat on co-
agulation factors and platelet aggregation was examined
Effect of the amount and type of dietary fat
Citation: Food & Nutrition Research 2014, 58: 25145 - http://dx.doi.org/10.3402/fnr.v58.25145 7
(page number not for citation purpose)(Appendix 3, Table 1e). Two studies where n-6 PUFA
(LA) and n-3 PUFA (ALA and/or fish oil) were comp-
ared showed no differences (45, 51). MUFA was bene-
ficial on platelet aggregation in one study as compared
with SFA (16). Fish oil (6 g/day) resulted in a lower
platelet thromboxane B2 concentration (28) and DHA
DPA (1.50.6 g/day) resulted in an increase in FVIIc as
compared with olive oil (32). The evidence was too scarce
to draw any conclusions (Appendix 7, Table 1e).
Altogether 12studies examinedtheeffect oftheamount
and/or quality of dietary fat on inflammatory markers
(Appendix 3, Table 1e). A summary is presented regarding
interleukin-6 (IL-6), C-reactive protein (CRP), and tumor
necrosis factor a (TNF-a) (Appendix 7, Table 1e), because
a variety of other inflammatory markers were included in
very few studies.
Regarding CRP, the effect of dietary fat was examined
in eight of the included studies. An intervention study
with both a fat-reduced and fat-modified diet resulted
in a significantly lower concentration than in subjects
consuming their usual diet with a higher content of total
fat, SFA, and cholesterol (60). One study found that
replacement of 8 E% SFAwith MUFA resulted in a lower
CRP concentration with a borderline significance (61),
whereas in another study no difference between the SFA
period and the MUFA period was found (23). A diet rich
in ALA (6.5 E%) and total PUFA (17 E%) resulted in a
lower high sensitive CRP concentration compared with
an average American diet with 0.8 E% ALA and 8.7 E%
PUFA (62). In a comparison of ALA and LA, ALA
resulted in lower CRP concentration in one study (63),
but not in the other (64). Three studies compared the
intake of fish oil with MUFA (32, 33, 65). One of these
showed a higher concentration of high sensitivity CRP
after the intake of fish oils as compared with high oleic
acid sunflower oil (65). The other two studies found no
difference between the diet groups.
IL-6 was measured in one study comparing MUFA,
SFA, and CHO (61). MUFA resulted in the lowest con-
centration. Comparisons of ALA and LA (63, 64) or
ALA and fish oil (58) showed no differences. In one
study, TNF-a was examined and no difference between
the ALA and LA diet groups was found (64).
In summary, because of conflicting results and scarce
data, no conclusions could be drawn regarding the effect
of the amount or quality of dietary fat on inflammatory
markers.
Six studies investigated the effect of the quality of
fat on intima media thickness and endothelial function
(Appendix 3, Table 1f), and all of them studied the effects
of n-3 PUFA, either of animal or plant origin. The study
by Zhao et al. (62) compared ALA and LA with an
average American diet. No effect was found in compar-
isons with LA, olive oil, or SFA (28, 33, 59, 63). Inter-
cellular adhesion molecule 1 (ICAM-I) and E-selectin
were lower on ALA and LA periods as compared with an
average American diet. ALA period resulted in lower
vascular cell adhesion molecule 1 (VCAM) and E-selectin
than LA (62). Systemic arterial compliance increased
both on a dose of 3 g/day of EPA or DHA as compared
with MUFA/olive oil (30). No conclusions could be
drawn (Appendix 7, Table 1e).
BW and body composition
The relationship between BW and reduced fat intake was
examined in four RCTs with a duration of 612 months
(48, 53, 54, 66), one of which also included a long-term
(5 years) follow-up (53) (Appendix 4, Table 2a). A high-
quality SR and meta-analysis of RCTs on fat intake and
CVD (67) also included BWas tertiary outcome. Another
high-quality SR and meta-analysis of RCTs, which spe-
cifically looked at the effect of fat intake and BW, was
included after the bibliographic search because of high
relevance (68). The studies were generally conducted in
healthy subjects with different BW status (BMI 2236 kg/m
2).
Most of the RCTs had one to six BW-related outcomes.
One of the RCTs found no significant effect on out-
come measures of adiposity (BW, fat mass, or waist cir-
cumference) (66), and one found an effect on four out of
six outcome measures (48). In two RCTs, a low-fat diet
(20 or 26 E%) resulted in greater weight loss than a
control diet (3437 E% fat) (53, 54). However, in one
of these studies (53), the difference was found at 1 year
only, with no significant difference at 5 years. The meta-
analysis by Hooper et al. (67) concluded that there was a
small significant effect of fat reduction on BWof around
1 kg. The subsequent meta-analysis of Hooper et al. (68)
included 33 RCTs and 10 PCS. Baseline fat intakes were
2843 E% and duration varied from 6 months to more
than 8 years. This meta-analysis found that interven-
tion with diets with reduced fat intake was associated
with lower weight gain of 1.41.6 kg. In nine studies that
reported BMI, lower fat intake was associated with a
significantly lower BMI of 0.51 kg/m
2. The meta-
analysis by Hooper et al. (67) included only two studies
on fat modification, which showed no effect on BW. One
of the included studies compared low-fat diets (2224
E%) with diets with higher fat content (3040 E%), either
high in MUFA or SFA, after an initial weight reduc-
tion with no significant differences in BW regain (48).
However, regain in body fat was lower on the low-fat and
high MUFA diets.
In summary, there was probable evidence for a mod-
erate direct association between total fat intake and BW
(Appendix 8, Table 2a).
Type 2 diabetes mellitus
The association between the risk of a T2DM and total fat
intake was examined in three PCS (6971) (Appendix 4,
Table 2b). Three PCS looked at the relationship with
PUFA (or LA) intake (6971), three at the intake of n-3
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These and other cohort studies were included in a SR
with 16 studies from 18 separate cohorts with a total of
540,184 individuals and 25,670 cases of incident T2DM
(74). The paper by Salmero ´n et al. (69) was not included,
although articles reporting results from longer follow-up
from the same cohort were included. The number of
subjects in the included PCS ranged from 3,0004,000 to
91,000, with a follow-up of 416 years. In addition, one
RCT examined the effect of a fat reduction from 34 to 26
E% on the risk of developing T2DM in 100 subjects with
impaired glucose tolerance (53).
Overall, total fat intake did not have an effect on
T2DM incidence (53, 6971). An increase in PUFA
intake as n-6 PUFA mainly (from 3 to around 6 E% in
exchange of CHO or SFA) may, however, be associated
with a T2DM risk reduction of around 20% (6971, 75).
Some PCS found that increased intakes of n-3
LCPUFA of marine origin, that is, EPA and DHA, were
associated with a 2040% increased risk of T2DM (70,
72, 73). In a SR and meta-analysis of 13 PCS conducted
in Europe, the United States, and Asia/Australia, no
overall association with intake of n-3 LCPUFA, assessed
as 0.3 g/day increment, was found (76). However, a sig-
nificant positive association with T2DM risk was found
in studies carried out in the United States (relative risk
(RR) 1.17, 95% CI: 1.091.26) (76). There was large hetero-
geneity among studies, and those using self-administered
FFQ were associated with higher, and significant, risk
estimates compared to interviewer-administered FFQ.
In an SR by Wu et al. (74), a meta-analysis showed
no significant association between dietary EPADHA
(16 PCS) and T2DM incidence (RR per 250 mg/day: 1.04
(95% CI: 0.971.10). No association for circulating levels
of EPADHA (5 PCS), assessed per 3% of total fatty
acids (RR 0.94, 95% CI: 0.751.17), was found. For
dietary ALA (7 PCS), the RR per 0.5 g/day was 0.93
(95% CI: 0.831.04) and for circulating ALA levels
(6 PCS) RR per 0.1% of total fatty acid was 0.90 (95%
CI: 0.801.00, p 0.06).
Tissue fatty acids and T2DM
Four PCS were identified with T2DM as outcome; two
regular cohort studies and two NCC studies were eva-
luated (7780) (Appendix 6, Table 4a). No PCS were
found that assessed fatty acids in other tissues. Two of
the evaluated studies assessed fatty acid composition in
erythrocytes (RBC), and the other studies assessed fatty
acid composition in serum or plasma lipid fractions, for
example, phospholipids (PL) and cholesteryl esters (CE)
or total serum lipids.
n-6 PUFA. LA was inversely related to diabetes risk in
three of the four studies (7880). In the NCC by Krachler
et al. (77), an inverse relation was found between LA in
RBC and T2DM, which did not remain significant in
multivariate analyses adjusted for age and HbA1c. The
latter may be because of over-adjustment as glucose levels
might well be in the causal pathway of LA and a T2DM
diagnosis. Taken together, the results imply that tissue LA
is inversely associated with development of T2DM.
n-3 PUFA. Tissue levels of ALA showed inconsistent
relations with the risk of T2DM as three out of four
studies found no significant relationships in the multi-
variate analyses (7779). However, one study did find an
inverse association between ALA in plasma PL, but not
in CE (80). Similarly, there was no significant association
between blood n-3 LCPUFA levels and the riskof T2DM
in any of the studies. Results from the SR and meta-
analyses by Wu et al. (74) also did not show any sig-
nificant association between circulating levels of EPA
DHA or ALA with T2DM.
SFA  Total and major SFA (14:0, 16:0, and 18:0).
In the ARIC-PCS total SFA and 16:0 in both PL and CE
were found to be directly associated with T2DM, whereas
18:0 was only significant in PL (80), in line with a similar
association between 18:0 in PL and total SFA with the
risk of T2DM in another PCS (79). In RBC, one study
showed borderline significant association between 18:0
and risk of T2DM (78), whereas no significant associa-
tions were found in another study measuring major
SFA in RBC, although 14:0, 16:0, and 18:0 were directly
related in a model adjusting for alcohol only, but not
after adjusting for HbA1c and BMI (77). The results
indicate a direct association between 18:0 and total SFA
with incidence of T2DM, but this relationship should be
interpreted with caution because major SFA including
18:0 are weak biomarkers of dietary SFA intake (81, 82).
Minor SFA (15:0 and 17:0). These SFA are not only
present in milk fat but also in fish and seafood in
amounts of 0.31 to 2.0% (83, 84). In the three studies
that included data on 15:0 or 17:0, there was an inverse
association with T2DM incidence for both in one study
(77), and with15:0 in another (79). In the study by Kro ¨ger
et al. (78), there was a trend for an inverse association
which did not reach significance in the multivariate
model. Because these studies were NCC studies without
any data from any original PCS, the data are limited-
suggestive to suggest an inverse relation between these
fatty acids and diabetes incidence. The odds ratios were
quite strong, and the data are consistent which strength-
ens the data for this finding.
In summary, there was probable evidence for an inverse
association for total PUFA or LA intake and T2DM.
This was further supported by suggestive evidence for an
inverse association between the major dietary n-6 PUFA,
that is, LA, and T2DM risk from biomarker studies.
There were limited data to draw any conclusions regard-
ing the association between intake of SFA and the risk of
T2DM. There was, however, limited-suggestive evidence
for an increased risk of major SFA (18:0) on T2DM risk.
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inverse association with the minor odd-chain SFA 15:0
and 17:0. The evidence for an association between dietary
total fat, ALA, and n-3 PUFA and T2DM was incon-
clusive (Appendix 8, Table 2b) and there was no evidence
of associations between neither plasma nor RBC ALA or
n-3 LCPUFA and T2DM risk (Appendix 10, Table 4b).
Cardiovascular diseases
Altogether 29 studies are included in the SR in which the
amount and quality of dietary fat on CVD risk was
studied (Appendix 4, Table 2c).
Total fat. The association between the intake of total
fat and mortality from CVD outcomes was examined in
four PCS (8588). Mean total fat intakes varied from
35 E% to about 45 E%. The Women’s Health Initiative
(WHI) RCT in 48,835 postmenopausal women (89) re-
ports on CVD outcomes from an intervention aimed at
reducing total fat intake to 20 E%, while maintaining
habitual fat intake in the comparison group (38 E%);
however, this goal was not reached (2830 E%). One SR
of RCTs also covered total fat intake (67). The results
from the RCTs and the SR showed no difference with
respect to the risk of any of the CVD outcomes. In the
PCS no significant effect of the intake of total fat on
CVD outcomes was found. In summary, a direct associa-
tion between total fat intake and CVD outcomes is
unlikely.
SFA. The association between SFA intake and CVD
outcomes was examined in seven PCS (57, 85, 87, 9092).
Most of the studies did not find any direct association
between the intake of SFA and risk of various CVD
outcomes. One prospective study in a multi-ethnic popu-
lation including 5,000 subjects, found that CVD risk was
dependent on food source of SFA (91). After 10 years of
follow-up, there was an overall inverse association with
CVD risk with SFA intake, assessed per 5 g/day (hazard
ratio (HR): 0.86, 95% CI: 0.75, 0.97) or 5 E% (HR: 0.71,
95% CI: 0.56, 0.89). Corresponding HRs for dairy SFA
were (per 5 E%) 0.62 (95% CI: 0.47, 0.82) and for meat
SFA (per g/day) 1.26 (95% CI: 1.02, 1.54). However, SFA
intake range was relatively narrow, about 6 E% in the
first and 12 E% in the fifth quintile, with a mean SFA
intake around 10 E%. A secondary analysis of the data
from the WHI RCT, showed that specifically lower intake
of SFA was associated with decreased risk of CHD in
women (89).
More recent studies have looked not only at the effect
of reduced SFA intake as such, but rather the effect of
specific substitutions with other macronutrients. In these
analyses, a reduction of SFA compensated by an increase
in the intake of CHO tended to be associated with in-
creased risk of CVD outcomes (87, 92, 93). This asso-
ciation seems to be dependent on type of CHO, with
increased risk with foods rich in simple CHOs, whereas
consumption of sources of more complex CHO did not
affect the risk (92). Similarly, a pooled analysis of data
from 11 PCS with around 350,000 men and women
observed a 20% decreased risk of CHD in both men
and women when 5 E% PUFA was substituted for equal
amounts of SFA (93). A SR concluded that there is mod-
erate evidence that substitution of unsaturated fatty
acids (MUFA or PUFA) for SFA can reduce CVD events
by 14% (67). The reduction in CVD events was seen in
studies of fat modification with duration of at least
2 years in which the risk reduction was 22%. Significant
risk reductions were seen in men, but not in women.
A meta-analysis of eight RCTs, including 13,614 partici-
pants, compared effect of interventions with increased
intake of PUFA as a replacement for SFA on CHD.
PUFA intake in the intervention groups was 15 E%, com-
pared with 5 E% in the control groups. Results showed
an overall significant risk reduction of 19%, correspond-
ing to 10% reduced CHD risk for each 5 E% increase of
PUFA intake. Studies of longer duration showed greater
benefits (94).
MUFA. The effect of dietary intake of MUFA was
studied in four PCS (57, 8587), in a pooled analysis by
Jakobsen et al. (93) and in a secondary analysis in an
RCT (89). None of these found any significant associa-
tion between MUFA intake and risk of CVD.
PUFA. Four PCS have examined the associations with
the intake of PUFA and CVD risk and none of them
found any significant direct association (57, 8587).
n-3 LCPUFA. Fourteen PCS examined the associations
between CVD outcomes and n-3 LCPUFA (95108).
Three of the studies used heart failure as the outcome and
none of these found any clear association (99, 101, 106).
In one study, no association with coronary calcification
was found (102). However, six of the studies found a sig-
nificant risk reduction for CVD, but in most cases only
for specific outcomes (ischemic stroke, sudden cardiac
death (SCD), fatal CHD, and CHD) (95, 96, 98, 100,
103105). In two studies with similar outcomes, no asso-
ciation was found (107, 108). One of the studies found
that the degree of risk reduction on sudden coronary
mortality decreased with age in men and was not sig-
nificant after the age of 65 years (100), which could
explain the lack of an effect in the studies where most of
the cases were above that age (99, 101, 102, 106). One of
the recent Scandinavian studies did find an increase in an
overall risk of CVD as well as in all its sub-disease classes
(CHD, stroke, and hypertension) at very low n-3 LCPU-
FA intake (50.06 g/day) compared with intakes  0.73
g/day in women aged 1647 with a follow-up of up to 12
years (105). The typical effect size was a risk reduction of
3060% at intakes  0.2 g/day. The associations were
linked to total fish intake. An SR and meta-analysis of
nine PCS concluded that intakes of dietary EPADHA
up to 0.20 g/day (mean intake) were associated with a
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95% CI: 0.450.89 per 0.20 g) (109). Mean or median
intakes in cohorts ranged from 0.04 to about 0.90 g/day.
Furthermore, one PCS found a lower risk of atrial
fibrillation (AF) at higher plasma levels of n-3 LCPUFA,
which was most pronounced for DHA (HR: 0.510.64
(0.320.92) (110).
ALA. Three of the six studies on CVD and dietary
intake of ALA found no association with CHD outcomes
(99, 104, 111), but one high-quality study found a sig-
nificant risk reduction of CHD with increasing ALA
intakes at low (B100 mg/day) n-3 LCPUFA intake. At
higher intakes of n-3 LCPUFA no association was found
(112). Two studies in which all subjects were B65 years at
baseline found a risk reduction for SCD and stroke (RR
around 0.50.6 at intakes  1 g/day) (113, 114). In one of
the PCS that did not find any association, the subjects
were around 70 years at baseline (111). No risk reduction
by n-3 LCPUFA was found in this same PCS (100). Two
of the studies have investigated potential interactions
between n-3 PUFA (ALA and n-3 LCPUFA) and n-6
PUFA (LA) and neither of them found any evidence for
such an effect (104, 112).
Biomarkers of the quality of dietary fat and CVD
The biomarkers in the included studies in this SR are
fatty acid composition of plasma, plasma lipids (PL or
CE), and RBC.
Cardiovascular mortality
Altogether six studies are included in the SR in which
fatty acid biomarkers of the quality of dietary fat on
CVD risk was studied (Appendix 6, Table 4b).
Two PCS showed inverse association with total PUFA
or LA in serum or CE, and CVD mortality and total
mortality (88, 115). Results from a NCC study among
elderly British men showed that a higher SFA proportion
in serum-PL was positively associated with CHD mor-
tality, whereas higher PUFA was inversely associated
with CHD mortality (116). Thus, these three studies
were consistent in reporting an inverse association with
especially n-6 PUFA (i.e. LA) and CVD mortality
in men.
Higher proportions of 16:0, 16:1, and 18:1 in serum CE
(1-SD increments) were associated with an increased risk
for stroke/transient ischemic attack (TIA) and brain
infarction (BI)/TIA in a PCS of men followed for 29
years (117). Higher proportions of LA were protective
against stroke/TIA and BI/TIA. No significant relation
between serum fatty acids and subsequent intracerebral
hemorrhage was observed (Appendix 6, Table 4b).
Regarding AF only one study was found. Higher
plasma levels of n-3 LCPUFA and especially DHA was
associated with lower risk of AF (HR: 0.510.64 (0.32
0.92) in multivariate analyses. ALA was not associated
with AF risk (110) (Appendix 6, Table 4b).
Regarding metabolic syndrome and inflammation,
only one PCS assessing association between tissue fatty
acids and inflammatory markers was included (118).
Proportion of LA in serum CE was associated with lower
plasma concentration of CRP, whereas oleic acid was
associated with higher CRP concentration. Because of
inclusion of one study only, no conclusion can be drawn
(Appendix 6, Table 4c).
Summary  CVD
There was found to be convincing evidence that partial re-
placement of SFAwith PUFA decreases the risk of CVD,
especially in men. Furthermore, there was some evidence
that the association between the type of fat and risk of
CVD is modified by the food sources. The evidence for
an association with total fat intake was considered to be
unlikely, at observed mean intakes ranging from about
30 to 45 E%. The evidence for an inverse association
with ALA and n-3 LCPUFA was found to be suggestive
(Appendix 8, Table 2c).
Cancer
Altogether 60 studies are included in the SR in which the
amount and quality of dietary fat on the risk of cancer
was studied (Appendix 5).
Total cancer
The WHI RCT reports on several cancer outcomes in-
cluding total invasive cancer incidence in 48,835 post-
menopausal women (119121). The intervention aimed at
reducing total fat intake to 20 E%, while maintaining
habitual fat intake in the comparison group (38 E%), but
the actual fat reduction was somewhat lower (2830 E%).
The intervention also included other dietary advice such
as increased intake of fruit and vegetables and wholegrain
cereals. There was no significant difference in total can-
cer incidence between the groups during the 8 years of
follow-up. One other PCS investigated the association
between total cancer incidence and intake of fish and
n-3 LCPUFA (97). No significant associations for n-3
LCPUFA were found during the 18 years of follow-up,
but the average intake of EPA and DHA in this study was
low compared to that in the Nordic countries.
Breast cancer
Total fat. Two RCTs investigated effects of reducing total
fat intake from 30 E% to about 20 E% or 38 E% to about
28 E%, respectively, on breast cancer risk in postmeno-
pausal women (119, 122). No significant differences were
found (Appendix 5, Table 3a).
Five PCS on postmenopausal breast cancer, reported
in six articles (123128), and two on premenopausal
breast cancer (129, 130) were also identified, which
included more than 670,000 subjects. For postmenopau-
sal breast cancer overall no significant associations were
found. In the study by Sonestedt et al. (123), a positive
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For premenopausal breast cancer a positive associa-
tion was found in one study (129). In the studies that
reported on ranges of total fat intake as E% in extreme
categories (quartiles or quintiles) these were 2429 E% to
]3445 E%. Results from three RCCs showed either no,
an inverse, or a positive associations (131133).
SFA. Six PCS reported on SFA intake, with non-
significant associations in five (124127, 129, 130). One
study found a positive association among menopausal
women who did not use hormone replacement therapy
(125). Results from the three RCCs showed no associa-
tions in two and an inverse association among normal-
overweight women (BMI B30 kg/m
2) (131133).
MUFA. Six PCS reported on MUFA intake, with non-
significant associations in five (124127, 129, 130). One
study found an inverse association among women age
50 years or more (126). Results from three RCCs showed
no associations in two, while an inverse association was
found among normal-overweight women (131133).
PUFA. The same six PCS reported on associations
between breast cancer and total PUFA intake, with non-
significant associations in five of the studies (124127,
129, 130), and only one study that found an inverse asso-
ciation among women above 50 years of age (126).
Results from three RCCs also showed no associations
(131133). In one of these studies only LA intake was
assessed (132).
Three PCS reported specifically on association be-
tween intake of n-6 PUFA and the incidence of breast
cancer (123125), two of these with non-significant asso-
ciations, and a positive association in one. One study
showed an inverse association in women in the highest
intake (fifth quintile) of n-6 PUFA intake (134).
The specific association for n-3 PUFAwas investigated
in several studies and the results from eight papers, which
included data from six different PCS, was analyzed in
an SR (135). The SR concluded that there is insufficient
evidence for an association between intake of n-3 PUFA
and breast cancer. Two subsequent PCS also reported
non-significant associations between breast cancer and
total intake of n-3 PUFA (124, 134). However, one of
these studies found an inverse association with n-3
PUFA among women in the fifth quintile of n-6 PUFA
intake (134). Results from two RCCs (132, 133) also did
not show any association between prevalent breast can-
cers and intake of n-3 PUFA. Two PCS have reported
associations with ALA intake (124, 134), but none of
them found an overall significant associations. However,
Thiebaut et al. (134) did find either inverse or positive
associations with ALA depending on food source.
The association between breast cancer and fatty acid
composition in tissues was examined also in four PCS.
These studies showed no consistent evidence for associa-
tions between proportion of any fatty acid in tissues
and the incidence breast cancer (136140) (Appendix 6,
Table 4d).
In summary, the evidence for an association between
fat intake and breast cancer was inconclusive (Appendices
9 and 10, Table 4c).
Other female specific cancers  ovarian cancer and
endometrial cancer
Ovarian cancer (Appendix 5, Table 3a). The WHI RCT
also investigated effects of a fat-restricted diet on ovarian
cancer (119). The results indicated a reduced incidence
in the intervention group compared to the comparison
group among women without prior bilateral oophorect-
omy at baseline. The HRover the whole 8-year follow-up
period was not significant. A pooled analysis of 12 PCS
did not find any significant association with total fat,
MUFA, or PUFA (141). For SFA, a weak, significantly
positive, but non-linear, association was found comparing
highest with lowest decile of intake. Results from sub-
sequent CCs show no associations with total fat or
subtypes (142, 143).
Endometrial cancer (Appendix 5, Table 3a). No sig-
nificant differences in endometrial cancer incidence were
seen during the follow-up period (8.1 year) in the WHI
RCT(119).Onemeta-analysiswasidentifiedthatincluded
two PCS and nine case-control studies (CC) (144) and the
results from this analysis did not show any significant
association between endometrial cancer and intake of
total fat or SFA in the PCS, but a positive association was
seen in the CC. A more recent PCS reported no overall
associations for total SFA, MUFA, PUFA, or n-3 PUFA
(145), although aborderline inverse association was found
comparing fat intake in highest versus lowest quartile.
In summary, the evidence for an association between
fat intake and ovarian cancer and endometrial cancer was
inconclusive. However, for ovarian cancer the evidence
for a positive association with the intake of SFA was
considered to be suggestive (Appendix 9).
Prostate cancer
A review and meta-analysis by Dennis et al. (146) covered
four PCS, published between 1989 and 1999, and it also
included 10 CCs published before 2000. The analysis by
Dennis et al. (146) found no significant associations in
studies where fat intakes were adjusted for energy, and
the results of the meta-analysis also did not show any
statistical associations between prostate cancer and any
of the other fat exposures (SFA, MUFA, or PUFA).
Three PCS on total fat, SFA, MUFA, and PUFA in
relation to prostate cancer risk published after 2000 were
identified (147149), but none of these studies showed
any significant associations. Another three CC studies
published after 2000 were also identified (150152) and
of these three studies, one found a positive association for
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found an inverse association for PUFA (Appendix 5,
Table 3b).
A review and meta-analysis by MacLean et al. (135)
focusing on n-3 PUFA covered six PCS, published be-
tween 1989 and 2004. Results showed no statistical asso-
ciation. In a subsequent study by Wallstro ¨m et al. (149),
no significant association was found for total n-3 PUFA.
A positive association was found for DHA, which ac-
cording to the authors may have been a chance finding.
A SR and meta-analysis of four PCS and one NCC
published between 1999 and 2007 found no significant
associations between intakes of ALA and prostate cancer
when extreme intake categories were analyzed (153).
In an analysis comparing fixed intakes (]1.5 vs. B1.5
g/day) a weak inverse association was found (pooled RR
0.95; 95% CI: 0.910.99). Two CC studies included total
and individual n-3 PUFA with inverse or no significant
associations (152, 154).
In summary, there was suggestive evidence for an in-
verse association between the intake of ALA with pro-
state cancer, but the association is likely to be non-linear.
Evidence for total fat and other fat subtypes were
inconclusive (Appendix 9).
Colorectal cancer
Total fat. In the WHI RCT, no significant difference in
colorectal cancer incidence was seen during the follow-
up period of about 8 years (121). Two PCS also
investigated association with total fat intake (155, 156),
and one of these did find a positive association with colon
cancer (155). Three CCs were identified (157159), all of
which reported non-significant associations (Appendix 5,
Table 3c).
SFA, MUFA, and PUFA. One PCS (156) and three
CCs (157159) investigated associations between color-
ectal cancer and intake of total SFA, MUFA, and PUFA.
None of the studies reported any significant associations
for any fatty acid category. One CC found an inverse
association with total n-6 PUFA only among subjects
with a fiber intake below the median (158).
n-3 PUFA. Eight PCS examined potential associations
with total or individual n-3 PUFA (135, 160). Seven of
these were included in an SR (135), which found no sig-
nificant associations between intake of n-3 PUFA and
colorectal cancer. One study found a positive association
in women but not in men (160). One CC found no asso-
ciations (161), whereas another found an inverse associa-
tion with total n-3 PUFA among subjects with a fiber
intake below the median (158).
In summary, the evidence for an association between
the intakes of total fat or fat types was limited
inconclusive (Appendix 9).
Lung cancer
One article was identified that reported results from
a pooled analysis of 8 PCS from Canada, Finland,
Netherlands, and USA with follow-ups of 616 years
(162). No significant associations were found between
intake of total fat, SFA, MUFA, or PUFA and lung
cancer (Appendix 5, Table 3e).
Other cancers
Pancreatic cancer (Appendix 5, Table 3e). Five PCS inves-
tigated associations with total fat intake (163167), of
which one found a positive and four no significant asso-
ciation. Total fat intake varied from 20 to 21 E% in the
lowest quintile to 3940 E% in the highest quintile. Four
PCS (163165, 167) and one CC (166) investigated asso-
ciations with SFA intake, of which two found a positive
and three no significant associations. SFA intake varied
from 56 E% in the lowest quintile to 1213 E% in the
highest quintile. Three PCS and one case-cohort study
investigated associations with total MUFA and PUFA
intake with no significant associations (163, 165167).
Esophageal cancer (Appendix 5, Table 3d). One PCS
investigated intake of total fat, SFA, MUFA, PUFA,
TFA, and total n-3 PUFA (168), with no overall sig-
nificant associations with cancer incidence. Sub-group
analyses revealed an inverse association for PUFA intake
among subjects with normal BMI (18.5 B25 kg/m
2,
HR for Q5 vs. Q1: 0.76; 95% CI: 0.630.92). One CC
investigated intake of total fat, SFA, MUFA, PUFA, and
several food groups in cases with esophagitis, Barrett’s
esophagus, and esophageal adenocarcinoma (169). For
adenocarcinoma increased risks were seen for highest
quintiles of total fat, SFA, and MUFA compared to
lowest quintiles.
Gastric cancer (Appendix 5, Table 3d). One PCS
investigated intake of total fat, SFA, MUFA, PUFA,
TFA, and total n-3 PUFA (168). There were no overall
significant associations with cancer incidence. One CC
investigated intake of total fat, SFA, MUFA, PUFA,
oleic acid, LA, ALA, vegetable and animal fat, and other
macronutrients (170). A strong significant inverse asso-
ciation was found for PUFA of n-6 PUFA mainly (OR:
0.66, 95% CI: 0.440.97) and LA (OR: 0.67, 95% CI:
0.451.00) when comparing highest and lowest tertile.
Renal cell cancer (Appendix 5, Table 3e). Two articles
reported results from 14 PCS (171, 172). The article by
Lee et al. (172) comprises results from a pooled analysis
of 13 PCS from Australia, Canada, Finland, Netherlands,
Sweden, and the United States with follow-ups between
7 and 20 years. No significant associations were found
between intake of total fat, SFA, MUFA, or PUFA and
renal cell cancer. Similarly, no significant associations
were found for intake of total fat, SFA, MUFA, or PUFA
in the EPIC-study with a mean follow-up of 8.8 years
reported by Allen et al. (171).
Effect of the amount and type of dietary fat
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tigated risk of bladder cancer with intake of total fat,
SFA, MUFA, or PUFA (173, 174). No significant asso-
ciations were found for total fat, SFA, and MUFA. One
of the two studies found an inverse association with total
PUFA and ALA (174).
Skin cancer (Appendix 5, Table 3e). One PCS in men
found an inverse association between intake of total fat
and riskof basal skin cancer after 8 years follow-up (175).
Further statistical analysis suggested that the association
was limited to MUFA. One CC found no association
between risk of squamous cell carcinoma of the skin with
intake of total fat, SFA, MUFA, PUFA, n-6 PUFA, or
n-3 PUFA (176). There was a tendency for decreased risk
in the highest ( 90th percentile) compared to the lowest
(B50th percentile) n-3 LCPUFA category (OR: 0.71,
95% CI. 0.491.00).
In summary, the evidence for an association between
fat intake and esophageal, gastric, bladder, and skin
cancers is limited and inconclusive. For renal cell cancer
the available evidence indicates that an association is
unlikely, For pancreatic cancer the evidence for an asso-
ciation was either inconclusive (SFA, n-3 PUFA) or
unlikely (total fat, MUFA, PUFA) (Appendix 9).
Overall mortality (all cause or from major chronic diseases)
In five studies included in this SR, the effects of the
amount and quality of dietary fat on overall mortality
was studied (Appendix 4, Table 2b). Two moderate-
quality PCS, both based on the same cohort from the
USA (97, 177), examined the effect of reduced fat intake
and/or modified quality of dietary fat (SFA reduction,
overall SFA/MUFA/PUFA, and increased n-3 LCPUFA)
on mortality over a 818 year follow-up period in
40,000 subjects. Results from the shorter follow-up found
that both a total fat intake of 530 E% and a SFA intake
B10 E% was associated with a 10% reduction in risk
(177), but there were no significant associations at the
18 year follow-up (97). The issue was also examined in a
high-quality SR and meta-analysis (67), which was based
on 21 RCTs, 71,000 subjects, and 4,292 deaths. It was
concluded that there was no evidence that a decreased
intake of total fat, a reduction in SFA, or a substitution
of unsaturated fatty acids for SFA was associated with a
significant reduction in overall mortality.
Two PCS and one NCC study showed inverse associa-
tion with total PUFA, n-6 PUFA or LA in serum or CE,
and CVD mortality and total mortality (88, 115, 116)
(Appendix 6, Table 4b).
In summary, results from RCTs and PCS do not sup-
port an association between total fat intake or fat quality
with mortality risk. However, there was suggestive evi-
dence of an inverse association between biomarkers of
PUFA or LA intake and CVD mortality (Appendix 10,
Table 4a).
Discussion
The objective of this SR was to assess all evidence
published between January 2000 and February 2012
regarding the effects of the amount and type of dietary
fat based on both dietary assessment methods as well
as biomarkers of intake using fatty acid composition in
various blood lipid fractions on risk factors for lifestyle
diseases such as T2DM and CVD, BW change, and
risk of clinical outcomes for CVD, T2DM, and cancer.
Articles focusing solely on the effect of TFA were
excluded as the intake of TFA has decreased considerably
during the last decades in the Nordic countries and are
well below current guidelines (2). Articles on the effects of
CLA or dietary cholesterol were also excluded.
The different outcomes for total fat and fatty acid
categories have been summarized in the result section.
The following discussion provides an overview of the evi-
dence regarding the major health outcomes (BW, T2DM,
CVD, and cancer) in relation to each of the fat categories
(total fat, SFA, MUFA and PUFA, n-6 and n-3 PUFA)
along with a comparison of the conclusions of this SR
with the conclusions of other recent SRs within each
field.
Effect of fat intake on metabolic risk markers
Based on modern genetic studies, LDL-C has been shown
to be causally related to atherosclerosis and LDL-C/
HDL-C and non-HDL-C are also known to be good
markers for CVD risk (178180). Plasma/serum LDL-C
has been identified as an important and causal risk factor
for atherosclerosis, whereas a high HDL-C concentration
and a low LDL-to-HDL-C ratio are associated with the
reduced riskof atherosclerosis. Higher risk profile already
in childhood has also been shown to be associated with
an increased risk of atherosclerosis and CHD (181, 182).
The relatively high-fat content with a high proportion
of SFA in the diet in the Nordic countries during the
1960s and 1970s have been considered as contributors to
the high prevalence of CVD. However, during the past
decades, there has been a significant decrease in CVD
morbidity and mortality in Finland, which previously
had the highest rate of CVD mortality in the world.
Simultaneously there has been a decrease in serum LDL-
C concentration. In women, the decrease in the intake of
SFA has been reported to explain 41% of the decrease in
LDL-C concentration. The equivalent degree of explana-
tion in men is 47% (183). Low HDL-C concentration and
elevated TAG concentration in plasma/serum have been
suggested to be independent risk factors for both T2DM
and CVD (184187), but their casual role has remained
unresolved. Recent genetic studies, however, suggest a
direct link of plasma/serum TAG concentration in the
development of CVD (188).
In line with several SRs and recommendations (2, 189),
the present SR found that a substitution of SFA with
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tions of total and LDL-C. A partial replacement of CHO
with MUFA or PUFAwas, however, not found to have an
impact on the lipid profile. This SR also included a few
studies which investigated effect of dietary fat on LDL
particle size, but no firm conclusions could be drawn on
this aspect.
Regarding comparisons of FO with other types of
PUFA, there do not seem to be differences regarding
serum/plasma total lipid or lipoprotein cholesterol con-
centrations. The evidence that FO lowers plasma/serum
TAG concentration as compared with MUFA was con-
sidered probable. In the other recent SRs (190192) n-3
LCPUFA has been shown to consistently lower plasma/
serum TAG concentration. There is suggestive evidence
that DHA increases serum/plasma LDL-C concentration
compared with MUFA. Because in some of the included
studies EPA and DHAwere studied instead of fish oil, the
specific effects of these two n-3 LCPUFAwere evaluated.
There is also some evidence that the effect of DHA on
plasma/serum TAG concentration may differ from that of
EPA. In the meta-analysis of Wei and Jacobsen (190)
consisting of 33 studies, both EPA and DHA were found
to decrease serum/plasma total TAG concentrations and
DHA was, furthermore, found to increase the concentra-
tions of both LDL-C and HDL-C. However, this meta-
analysis also included studies on non-Caucasians and did
not differentiate between studies which used MUFA or
other type of PUFA as the control. Compared with the
effect of n-3 LCPUFA, the effect of ALA on plasma lipid
profile is not examined as thoroughly and the evidence
regarding potential beneficial effects are therefore not as
clear (193, 194).
When it comes to the effects on fasting serum/plasma
glucose concentrations, none of the fat exposures, includ-
ing substitution of SFA with MUFA and/or PUFA were
found to have any effect on plasma glucose concentra-
tions in healthy people or people at risk with quite
normal fasting glucose concentrations. Furthermore, no
conclusions could be drawn from comparisons of the
effects of MUFA or PUFA and SFA on insulin sensitivity
measured either by SI or HOMA-IR. On the contrary,
when MUFA and CHO was compared with SFA, MUFA
resulted in better HOMA-IR or SI or fasting serum/
plasma insulin concentration when compared with SFA
(24, 4749) and this was confirmed by effects on glycated
hemoglobin in a sub-study (27) of Due et al. (48). Thus,
overall the evidence was considered as probable for a
beneficial effect of MUFA and CHO versus SFA on
insulin sensitivity. In two recent intervention studies in
obese subjects with the metabolic syndrome no effect of
reducing the intake of SFA on SI was found (195, 196).
The report by FAO (2) concluded that there was a
possible favorable effect of replacing CHO with MUFA
on insulin sensitivity. The amount of total fat may modify
the effect of the quality of fat as a study by Vessby et al.
(19) found in a secondary analysis that replacing SFA
with MUFA improved insulin sensitivity in particular in
healthy subjects when total fat intake was below 37 E%,
which may explain why no effect was observed in some of
the studies that had a high-fat intake. Animal studies
have indicated that n-3 PUFA have a beneficial effect on
glucose homeostasis and insulin sensitivity (197, 198), but
based on the studies in this SR, no conclusions can be
drawn regarding the effects of n-3 LCPUFA from fish
oil supplements on insulin sensitivity or serum/plasma
glucose and insulin concentrations. This is in line with the
conclusion in other reviews that have evaluated the
evidence from studies in humans (199).
Only few of the included studies, examined the effect of
the total amount of fat on BP and no conclusions could
be drawn. Conclusions regarding the effect of the quality
of fat on BP were inconclusive as well. In four included
studies the one by Bos et al. (11) and the cohort study
by Wang et al. (57) showed no difference, whereas in
studies by Gulseth et al. (55) and Rasmussen et al. (56) a
MUFA-rich diet resulted in lower BP than a SFA-rich
diet. Interestingly, in a study by Rasmussen et al. (56) the
response to the change in the quality of fat was only seen
in those subjects whose fat intake was below 37 E%.
In a study by Bos et al. (11) the intake of fat was about
40 E%. In a cross-sectional INTERMAP study, including
also non-Caucasian populations, dietary total PUFA,
n-3 LCPUFA as well as ALA and gamma-linolenic acids
were inversely related to BP, also in normotensive
subjects (200).
No conclusion could be drawn regarding the effect of
n-3 LCPUFA on BP. In the meta-analysis by Geleijnse
et al. (201), n-3 LCPUFA was found to reduce BP,
although mostly in subjects who were  45 years or
hypertensive.
New cardiovascular risk markers are emerging and
several of the included studies have examined effects of
dietary fat on markers of coagulation and inflammation.
There are, however, generally only a few studies with the
same combination of fat exposure as these risk markers
so it was not possible to draw any conclusions from these
studies.
One of the studies used ex vivo platelet aggregation as
a method to assess coagulation, but this method may not
be applicable for in vivo conditions. The results of the
included studies on coagulation were quite inconsistent
and some results indicate that sex may modify the effect
of dietary fat (202). The n-3 PUFA are generally said
to be antithrombogenic although in high doses (203).
However, no conclusions could be drawn from the studies
included in this SR. It is of note, that the effect of specific
n-3 LCPUFA, namely EPA and DHA, on coagulation
may differ (202).
Effect of the amount and type of dietary fat
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(in the lower range) has been established as an indepen-
dent marker of CVD (204). Very few of the included
studies examined associations between dietary fat and
CRP. Unsaturated fatty acids, that is, MUFA, PUFA, or
n-3 LCPUFA were not found to have beneficial effects in
any of the included studies. However, SFA was not better
than unsaturated fat in any of the studies. There were five
studies for intima media thickness or endothelial function
includedinthisSRandtheresultsfromthesedidnotallow
any clear conclusions to be drawn.
Body weight
Obesity is generally considered to be one of the most
dominating modifiable determinants of lifestyle diseases
(205). Obesity is, however, a gradually developing condi-
tion and none of the included studies examined fat
intake and long-term risk of obesity, because this aspect
was covered by another recent SR (206). The present SR
focused on the effects of the amount and qualityof dietary
fat on changes in BW. The studies that investigated the
effect of fat intake and dietary fatty acid composition on
BW included one very large SR and meta-analysis (67)
and generally show that fat quality has no impact on BW.
The effect of the amount of fat on BW was variable in the
included studies. A reduction in an overall intake of fat
below 30 E% seemed to be associatedwith modestly lower
BW. The high-quality SR and meta-analysis of RCTs and
PCS by Hooper at al. (68) concluded that a reduction in
fat intake resulted in lower weight gain of 1.41.6 kg on
average. Baseline fat intakes in the studieswere 2843 E%,
which covers ranges observed in Nordic populations.
It was concluded that there is probable evidence for a
moderate association between total fat intake and BW.
However, other dietary factors such as type and amount
of CHO and protein may interact as well (206).
Type 2 diabetes
No association with the riskof T2DM and n-3 LCPUFA,
MUFA, or total fat intake was found. However, probable
evidence was found that LA intake reduces the risk of
T2DM, which is in agreement with the conclusion in the
FAO report (2). This conclusion was based on studies
where increased mainly n-6 PUFA (from 3 to around
6 E%) at the expense of SFA or CHO was found to be
associated with a risk reduction of T2DM of around 20%.
This association was supported by suggestive evidence for
an inverse association between levels of LA in serum-PL
and RBC and reduced T2DM risk, with a similar effect
size (RRof around 2040%). This effect is also supported
as results from RCTs have suggested a moderate in-
sulin sensitizing effect of n-6 PUFA compared with SFA
(17, 207).
In long-term RCTs, a reduced intake of fat and SFA in
combination with modest weight reduction, increased
intake of dietary fiber, and increased physical activity has
been shown to reduce the risk of T2DM in subjects with
glucose intolerance even many years after the active
intervention (208212). In the Finnish Diabetes Preven-
tion Study, increased risk of diabetes was associated
with a diet high in fat and low in CHO, whereas a diet
reduced in fat and higher in CHO has been found to be
protective (209).
In a recent report by FAO, SFAwas considered to have
a possible positive relationship with increased risk of
T2DM (2). However, this SR did not find any clear asso-
ciations between intake of SFA and T2DM. In one of the
three identified PCS, SFA intake was associated with a
higher risk of T2DM, but this association was not inde-
pendent of BMI (75). Increased serum SFA has recently
been shown to be associated with insulin resistance,
elevated serum glucose concentration, and tissue inflam-
mation (213). In the present SR, there were limited data
to draw conclusions with respect to circulating levels of
major SFA, although the studies did suggest a positive
association, which was however only seen with SFA in
plasma lipids, and not with RBC. Data regarding cir-
culating levels of SFA are however difficult to interpret as
the correlation with intake is generally poor (214), except
for the odd-chain SFA that are not synthesized endogen-
ously. The SR found suggestive evidence that the minor
odd-chain SFA (15:0 and 17:0), which are produced by
micro-organisms in the rumen of cows and are thus found
in milk fat, are inversely associated with risk of T2DM.
However, 15:0 and 17:0 is also found in fish (83, 84, 214).
Thus, controlled studies are needed to understand the
significance of these inverse associations. High-fat dairy
products, for example, butter, have not been found to
have favorable effect on insulin sensitivity or b-cell func-
tion, when compared with n-6 PUFA or MUFA in short-
term RCTs (19, 207). However, there might be differences
between the effect of different types of dairy products
on glucose metabolism and other components in dairy
products may explain the association, so further studies
are needed in this respect.
Some of the included PCS indicate that high intake of
n-3 LCPUFA may be associated with increased risk of
T2DM, which is surprising and in contrast to hypothesis
based on the effect of n-3 LCPUFA on insulin resistance
in rodents and the before mentioned effect on various
risk markers (197, 198). However, a recent SR and meta-
analysis (74) found that intake of EPA and DHAwas not
associated with either a favorable or a harmful effects on
the risk of T2DM. The meta-analysis also showed that
intake of ALA, was not associated with a reduced risk of
T2DM, but circulating ALA levels were suggested to be
associated with modestly lower risk of T2DM. However,
the present SR did not find any evidence that plasma or
RBC ALA or intake of ALA were related to T2DM risk.
The report by FAO (2) concluded that there was
possible evidence that total PUFA intake was associated
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inverse association between the major dietary n-6 PUFA,
LA (in serum-PL and RBC) and the risk of T2DM was
suggestive. A possible moderate insulin sensitizing effect
of n-6 PUFA has been suggested in some RCTs, when
compared with SFA (17, 207).
Cardiovascular diseases
Risk of CVD was in this SR not found to be modified by
the total dietary fat intake at observed mean intakes from
about 30 E% to 45 E%, but the results indicate effects of
fat quality. A pooled analysis of data from PCS showed
a 20% reduction in the risk of CHD in both men and
w o m e nw h e np a r to fS F Aw a sr e p l a c e dw i t hP U F A ,m a i n l y
n-6 PUFA, whereas the risk was increased by when SFA
was replacedwith CHO (93). This association seems to be
dependent on type of CHO. In a PCS replacement of
SFA by CHO with high glycemic index increased the risk
of myocardial infarction whereas a replacement by CHO
with low glycemic index did not affect the risk (92). The
FAO report, however, evaluated that replacement of fat
with ‘refined’ CHO is probably not associated with an
increased risk, but may support the development of the
metabolic syndrome (2). CHD is rare in populations with
very low intake of both total fat and SFA (B15 E% and
B5 E%, respectively) (215). This discrepancy is most
likely explained by the quality of CHO in the diet and
lower BMI as well as the level of physical activity (92,
216). Circulating levels of some major SFA was in a
couple of studies found to be related to overall and CVD
mortality, but these data should be interpreted with
caution since tissue SFA is a weak dietary biomarker as
previously mentioned. Thus, the SR concluded that there
is convincing evidence that partial replacement of SFA
with mainly PUFA can reduce CVD events by around
1020%, whereas the total amount of fat did not affect
the CVD risk (67, 93, 94).
A recent large NCC including both women and men
found an inverse association between plasma PL n-6
PUFA (LA in particular) and CHD during a 13-year
follow-up and the association was independent of sex
and several other confounders (217). Similar results were
seen in three studies in North European populations,
the United Kingdom, Sweden, and Finland, which was
included in this SR (88, 115, 116). Since LA is one of the
strongest dietary fatty acid biomarker (mainly reflecting
overall intake of PUFA from vegetable oils) the associa-
tions are relevant. The inverse association between LA is
thus well in accordance with the results based on dietary
intakes (93, 94). With respect to n-3 PUFA  ALA or n-3
LCPUFA  two of the included biomarker studies on
ALA and CVD indicated a potential beneficial effect
(113, 114), whereas no effect of ALA was found in three
studies (99, 104, 111). In the study by Mozaffarian et al.
(112), a beneficial effect of increasing ALA intakes on
CHD events was only evident at concomitant low n-3
LCPUFA intake (B100 mg/day), indicating that the
association with ALA may be modified by n-3 LCPUFA
intake. The ratio between n-3 and n-6 PUFA was not
found to have an effect on CVD risk (104, 112). This is in
line with the conclusions by FAO/WHO (2).
The intake of n-3 LCPUFA of marine origin had bene-
ficial effects on CVD incidence and mortality in several
studies, but intakes  0.200.25 g/day had no or limited
effect in most of the studies. The effect seems to be limited
to specific CHD outcomes. According to the guidelines by
European Society of Cardiology (189) the evidence of the
efficacyof total PUFA in secondary prevention in AF was
considered limited because of the controversial results.
The recent SR and meta-analysis by Rizos et al. (218)
concluded that n-3 LCPUFA supplementation was not
associated with an overall lower risk of mortality in CHD
patients but did find a significant reduction in cardiac
death (RR 0.91; 95% CI: 0.850.98).
Some major SFA was related to CVD mortality in two
studies (115, 116) and overall mortality in one study
(115). The data on SFA should, however, be interpreted
with caution because they are much weaker dietary bio-
markers than LA, ALA, and n-3 LCPUFA (EPA and
DHA), as well as the minor 15:0 and C17:0 found in milk
fat and fish (81, 214).
Cancer
We included two moderate-quality studies (one RCT and
one PSC) that examined the association between total fat
intake and total cancer incidence in women. These studies
found no significant effect of either with total fat intake
(97, 119) or n-3 LCPUFA intake (97). Breast cancer is the
major cancer type in women, and the studies included in
this SR also did not find any association between risk of
breast cancer and the intake of total fat in postmeno-
pausal women, but BMI may modify the association
(123). However, a positive association was found in pre-
menopausal women in one of the two included studies
(129). Data suggest that the associations may be modified
by several factors, for example, hormone replacement
therapy (125), age (126), and dietary source of concomi-
tant intake of n-3 and n-6 PUFAs (134). Results from
studies using tissue markers of dietary fat intake do not
show any consistent relation.
This SR found limited and inconclusive evidence link-
ing intake of total fat or quality of fat with endometrial,
colorectal, or pancreatic cancer. However, for ovarian
cancer, the evidence for a positive association with the
intake of SFA is suggestive as it is for prostate cancer
for an inverse association with the intake of ALA. No
associations were found for prostate cancer, esophageal
cancer, gastric cancer, renal cell cancer, bladder cancer,
lung cancer, or skin cancer by the total intake or types of
dietary fat.
Effect of the amount and type of dietary fat
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conclusions from the World Cancer Research Fund
(WCRF) report (219). However, the report concluded
that there is limited-suggestive evidence for a link between
total fat and an increased risk of postmenopausal breast
cancer and lung cancer and also limited-suggestive evi-
dence that foods containing fat of animal origin are
linked to increased colorectal cancer risk. According to
the WCRF/AICR report (219) there is an indirect link
between energy-dense diets and cancer and the evidence
indicates a probable or convincing link between body
fatness and most cancer types.
Methodological considerations
The database searches included studies published in
20002012. The reason for not including older articles
was that we focused on new evidence that has evolved
since the previous edition of NNR (10). However, several
SRs and meta-analyses that included previous publica-
tions were identified and evaluated which likely adds
confidence to the results. Although we used structured
terms and free text in the searches, additional relevant
articles were identified by the experts via ‘snowballing’
and reference lists, thus emphasizing the importance of
expertise in the various research fields.
The use of a structured guide, which included a tool for
assessing study quality and criteria for evidence grading,
facilitated objective evaluation and judgment (A guide
for conducting Systematic Literature Reviews for the fifth
edition of the NNR). The guide builds on several other
established guidelines developed by, for example, WCFR/
AIRC (219), US Agency for Healthcare Research and
Quality (220), and the Swedish Council on Health Tech-
nology Assessment (221). Combination with predefined
inclusion and exclusion criteria of studies minimizes bias.
However, criteria for both study quality and evidence
grading were strict, resulting in relatively conservative
estimates of the evidence, which is also to be taken into
account in the discussion where the results of this SR
were compared with other SRs and meta-analyses.
In general, there were very few studies graded as high
quality (A). Most of the articles were graded as moderate
(B), or low (C) quality. This does not mean that all of
these studies were of lower quality. A common reason for
lower rating was lack of details on methodological issues
such as recruitment, dropout, compliance, statistical
methods, and dietary intakes. This highlights the need
for improved criteria and requirement for reporting in
published articles.
The studies on metabolic risk markers were all RCTs
except one. The number of subjects varied from 14 to
1,720. It was striking that most of the studies did not use
any biomarkers for the compliance to the intervention
diets. Only few conclusions can be drawn on the quality
of fat on risk markers because of the heterogeneity of
comparisons which leads to small number of studies per
each comparison.
Many aspects of the intake of fat and the quality of
dietary fat have been studied and generally there are only
few articles within each of these aspects that look at the
effects on hard clinical endpoints in healthy people within
the period that is evaluated in this SR. In most cases
studies that look at effects on hard clinical endpoints are
also mostly observational and only a few of them make
proper adjustments for the intake of other nutrients 
specifically the intake of total energy, CHO, and protein 
as specified in the research question. The endpoint of
interest also affects the optimal conduction of a study.
Weight maintenance and obesity are easier to investigate
by an RCT, whereas the development of CVD and cancer
need more long-term studies and are therefore more
difficult to be examined in RCTs. For CVD, there are a
number of well-characterized metabolic risk markers that
are used as indicators of the risk. This is, however, not the
case for cancer and there are also relatively few PCS
within this field. Despite this, RCCs within this area were
not included in drawing the conclusions because of a
number of confounding factors typical to this study type.
The impact of dietary assessment method on clinical
outcomeshasbeendiscussed,especiallyinepidemiological
studies regarding dietary fat and breast cancer (120, 222).
Results from statistical analysis of data from diet records
and FFQs indicate that FFQs may result in imprecise
intake estimates and thus may underestimate true associa-
tions. More recent epidemiological studies have, however,
not shown any significant differences between risk esti-
mates based on FFQs or dietary records (133).
Results from current Nordic dietary surveys show that
the average total fat intake is 3137 E% in the general
adult population, with SFA contributing 1214 E% and
PUFA contributing 56 E%. In view of the results of the
current SR, focus should be on replacing part of SFA
with PUFA and/or MUFA. During the past decade,
intake of TFA in the Nordic countries has decreased to
0.50.6 E%. It is prudent to keep the intake at a low level,
as there are several documented and potential health
consequences of elevated intakes (2).
This SR has reviewed a large number of studies, involv-
ing several hundred thousand participants, focusing on
different health outcomes. Despite the vast research efforts,
many questions remain unresolved, mainly because of
conflicting results from studies and lack of high-quality
controlled studies. There is thus an evident need for
highly controlled RCTs and PCS with sufficient number
of subjects and long enough duration on the effects of
the amount and quality of fat, especially regarding insulin
sensitivity, T2DM, low-grade inflammation, and BP.
It is warranted to find new surrogate markers for CVD.
Furthermore, using the new methodology available for
Ursula Schwab et al.
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